Healthcare · Biotechnology · NASDAQ

First Tracks Biotherapeutics (TRAX) Stock Price, Analysis & Trade Signals

$47.10-1.6 (-3.29%)

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

TRAX key stats

Market Cap
$1.98B
P/E Ratio
0
EPS
-4.71
52 Week Range
$0.00 – $54.78
50-Day Avg
39.90
200-Day Avg
32.25
Revenue Growth (Qtr YoY)
0%
Profit Margin
0%
Operating Margin (TTM)
0%
Volume
462.24K
30-Day Avg Volume
769.46K
Next Earnings
Feb 2, 2027
Estimated EPS
-0.73
CEO
Daniel R. Faga
Employees
104
IPO Date
Apr 20, 2026

TRAX analyst rating & price target

12 analysts rate TRAX Buy on consensus.

3Strong Buy
9Buy
0Hold
0Sell
0Strong Sell

Consensus price target: $75.17 (+59.6% upside from $47.10)

First Tracks Biotherapeutics annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$0—$-166.09M
2024$0—$-163.71M
2023$0—$-106.15M

Stock data for TRAX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics